Hospira UK Ltd v Genentech, Inc. [2015] EWHC 1796 (Pat), [2015] All ER (D) 33 (Oct)
The Chancery Division held that the claimant’s claim of invalidity regarding the defendant’s patent for a product for the treatment of HER2-positive breast cancer would be allowed, where the defendant’s patent was novel, but obvious over prior art.